Cost-effectiveness analysis of the addition of bevacizumab to first-line chemotherapy in metastatic colorectal cancer

被引：0
|
作者：
Villa, D.
Hedden, L.
Peacock, S.
Kennecke, H. F.
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] British Columbia Canc Res Ctr, Vancouver, BC V5Z 1L3, Canada
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2010年 / 28卷 / 15期
关键词：
D O I：
10.1200/jco.2010.28.15_suppl.3623
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3623
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Bevacizumab in addition to chemotherapy first-line for right-side metastatic colorectal cancer: A cost-effectiveness analysis.
    Chen, Gong
    Liu, Maobai
    Li, Te
    Wu, Bin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [2] Cetuximab and bevacizumab in addition to chemotherapy first-line for left-side metastatic colorectal cancer: A cost-effectiveness analysis.
    Zhang, Yanqiao
    Zheng, Tongsen
    Liu, Maobai
    Li, Te
    Wu, Bin
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [3] Addition of Bevacizumab to First-Line Chemotherapy for Metastatic Colorectal Cancer
    Tsutsumi, Soichi
    Fujii, Takaaki
    Yamaguchi, Satoru
    Suto, Toshinaga
    Yajima, Reina
    Morita, Hiroki
    Kato, Toshihide
    Asao, Takayuki
    Kuwano, Hiroyuki
    [J]. HEPATO-GASTROENTEROLOGY, 2014, 61 (131) : 633 - 637
  • [4] The cost-effectiveness of bevacizumab in the first-line treatment of metastatic colorectal cancer in England and Wales
    Tappenden, P.
    Jones, R.
    Paisley, S.
    Carroll, C.
    [J]. EUROPEAN JOURNAL OF CANCER, 2007, 43 (17) : 2487 - 2494
  • [5] Cost-Effectiveness Analysis of Monoclonal Antibodies Associated With Chemotherapy in First-Line Treatment of Metastatic Colorectal Cancer
    Barufaldi, Laura A.
    de Albuquerque, Rita de C. R.
    do Nascimento, Aline
    Martins, Luis Felipe L.
    Zimmermann, Ivan R.
    de Souza, Mirian C.
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2023, 37 : 33 - 40
  • [6] First- and Second-Line Bevacizumab in Addition to Chemotherapy for Metastatic Colorectal Cancer: A United States-Based Cost-Effectiveness Analysis
    Goldstein, Daniel A.
    Chen, Qiushi
    Ayer, Turgay
    Howard, David H.
    Lipscomb, Joseph
    El-Rayes, Bassel F.
    Flowers, Christopher R.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (10) : 1112 - 1118
  • [7] Cost-effectiveness of biomarker-directed bevacizumab for first-line therapy of persons with metastatic colorectal cancer
    Berry, Kristin
    Bensink, Mark Eliot
    Musa, Zahra
    Shankaran, Veena
    Lin, Edward H.
    Ladabaum, Uri
    Bodnar, Carolyn
    Birt, Michael
    Ramsey, Scott David
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [8] Atezolizumab with chemotherapy in first-line treatment for metastatic urothelial cancer: a cost-effectiveness analysis
    Zhang, Peng-Fei
    Wen, Feng
    Wu, Qiu-Ji
    Li, Qiu
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2022, 11 (14) : 1021 - 1030
  • [9] Cost-effectiveness of capecitabine and bevacizumab maintenance treatment after first-line induction treatment in metastatic colorectal cancer
    Franken, M. D.
    van Rooijen, E. M.
    May, A. M.
    Koffijberg, H.
    van Tinteren, H.
    Mol, L.
    ten Tije, A. J.
    Creemers, G. J.
    van der Velden, A. M. T.
    Tanis, B. C.
    Groot, C. A. Uyl-de
    Punt, C. J. A.
    Koopman, M.
    van Oijen, M. G. H.
    [J]. EUROPEAN JOURNAL OF CANCER, 2017, 75 : 204 - 212
  • [10] Cost-Effectiveness of First-Line Cetuximab in Metastatic Colorectal Cancer in Saudi Arabia
    Elsamany, Shereef
    Elsisi, Gihan Hamdy
    Hassanin, Fayza Ahmed Mohamed
    Saleh, Khaldoon
    Tashkandi, Emad
    [J]. VALUE IN HEALTH REGIONAL ISSUES, 2022, 28 : 67 - 75
12345